1. Tahlil KM, Pettifor AE, Edwards JK, Tang W, et al.
   Uptake of facility-based HIV testing among adolescents and young adults in Nigeria.
   AIDS 2025.
   


2. Malama K, Parker R, Wall KM, Kilembe W, et al.
   HIV incidence and risk factors for seroconversion among female sex workers and single mothers in a 10-year prospective cohort.
   AIDS 2025.
   


3. Diggs MR, Chu SM, Fitch KV, Olefsky M, et al.
   Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.
   AIDS 2025.
   


4. Zhu X, Patel EU, Berry SA, Lucas GM, et al.
   Hospital readmissions among adults with chronic kidney disease by HIV status in the United States.
   AIDS 2025.
   


5. Knight J, Ma H, Sithole B, Khumalo L, et al.
   Evaluating the impact of achieving cascade equality in Eswatini: a modelling study on the prevention impacts of antiretroviral therapy.
   AIDS 2025.
   


6. Shiino T, Chikata T, Hayashida T, Tran LK, et al.
   Epidemiological Links of HIV-1 CRF01_AE among Men Who Have Sex with Men in Northern Vietnam and Japan.
   AIDS 2025.
   


7. Okhagbuzo MI, Njuguna I, King'e M, Moraa H, et al.
   Lower working memory and processing speed among children and youth exposed to HIV.
   AIDS 2025.
   


8. Li QH, Zhao J, Hu SP, Wang FX, et al.
   A novel second-generation HIV-1 circulating recombinant form (CRF183_0107) identified among men who have sex with men in China.
   AIDS 2025.
   


9. Carratala Castro L, Munguambe S, Kay A, Ssengooba W, et al.
   Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM).
   Clin Infect Dis 2025.
   


10. Bercot B, Assoumou L, Camelena F, Voitichouk C, et al.
    Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial.
    Clin Infect Dis 2025.
    


11. Kenyon C.
    Screening for anal cancer is associated with real harms and questionable benefits.
    Clin Infect Dis 2025.
    


12. van der Wulp IAJ, Wit FW, Jongen VW, Brinkman K, et al.
    Earlier initiation of treatment following HIV acquisition reduces non-AIDS-defining malignancy risk.
    Clin Infect Dis 2025.
    


13. Crum N.
    Let's Get It Started: Early ART after HIV Acquisition Reduces Non-AIDS-Defining Malignancies.
    Clin Infect Dis 2025.
    


14. Toy M, Hutton D, Teshale E, Thompson WW, et al.
    Cost-Effectiveness of One-time Universal Testing for Hepatitis D among Adults living with Chronic Hepatitis B in the United States.
    Clin Infect Dis 2025.
    


15. Chung JR, Price AM, Zimmerman RK, Moehling Geffel K, et al.
    Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season.
    Clin Infect Dis 2025.
    


16. Hanscom B, Marzinke MA, Li X, Donnell D, et al.
    Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083.
    J Infect Dis 2025.
    


17. Selzer L, Demirdjian S, Falkard B, Li J, et al.
    Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment with Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab.
    J Infect Dis 2025.
    


18. Nasir MW, Gao Y.
    Advances in KSHV Research: Molecular Pathogenesis, Immune Evasion, and Evolving Therapeutic Horizon.
    J Med Virol 2025;97:e70695.
    


19. Casado-Fernandez G, de la Calle-Jimenez O, Armenteros I, Lemus Aguilar L, et al.
    Changes in HIV-1 Reservoir Dynamics After Mpox Infection.
    J Med Virol 2025;97:e70690.
    


20. Jamieson PJ, Shen X, Abu-Shmais AA, Wasdin PT, et al.
    Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
    J Virol 2025.
    


21. Karim QA.
    Lessons from Africa: health diplomacy in HIV prevention.
    Lancet 2025.
    

Display articles in

• Abstract format